Is 2157.HK overvalued or undervalued?

2157.HK currently has a P/E ratio of 24.13. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Lepu Biopharma Co., Ltd. stock?

Lepu Biopharma Co., Ltd. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2157.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2157.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2157.HK to protect their purchasing power. Because 2157.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2157.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2157.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2157.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2157.HK

Lepu Biopharma Co., Ltd.

HK$3.82-HK$0.03-0.65%

HKSE / HKD

Market cap

HK$6.9B

P/E

24.1

EPS (TTM)

HK$0.02

Dividend yield

0.00%

Beta

-0.42

1Y return

-47.16%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$2M2022

$32M2023

$50M2024

$130M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.84Low
Current ratio1.14
Cash ratio0.67
Net margin24.9%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2157.HK24.1
Healthcare sector median26.8
S&P 50022.0

Trades about 10% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.11
Price to book4.16
EPS (TTM)HK$0.02
Payout ratio0%
FCF yield-1.06%

Range & risk

HK$3.55HK$7.32

Trading in the lower third of its 52-week band

Beta-0.42

Profile

What Lepu Biopharma Co., Ltd. actually does

Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.

CEO

Sui Ziye

Employees

646

Headquarters

Shanghai, SH

Founded

2022-02-23

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2157.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2157.HK has a beta of -0.42, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Lepu Biopharma Co., Ltd.